BCL7A

Across TCGA pan-cancer cohorts, BCL7A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCL7A data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BCL7A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BCL7A expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where BCL7A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.994	0.883	<.001	65	view →
LUAD	OS	Tertile	II,III,IV	0.822	0.442	.022	7	view →
PDAC	DFS	Median	IV	0.766	0.234	.026	5	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →
HNSC	OS	Median	All	1.000	0.964	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BCL7A–LSCC (DFS)

Open the LSCC breakdown →